Citadel Advisors’s Cellectis CLLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-1,700
Closed -$3.06K 14584
2024
Q4
$3.06K Buy
1,700
+300
+21% +$560 ﹤0.01% 14028
2024
Q3
$3K Buy
1,400
+300
+27% +$652 ﹤0.01% 13701
2024
Q2
$2.06K Buy
+1,100
New +$2.89K ﹤0.01% 13739
2024
Q1
Sell
-1,400
Closed -$4.31K 14639
2023
Q4
$4.31K Buy
1,400
+600
+75% +$1.42K ﹤0.01% 13516
2023
Q3
$1.26K Sell
800
-300
-27% -$586 ﹤0.01% 13888
2023
Q2
$2.17K Buy
+1,100
New +$2.11K ﹤0.01% 13817
2023
Q1
Sell
-1,500
Closed -$3.15K 14800
2022
Q4
$3.15K Buy
+1,500
New +$3.4K ﹤0.01% 14245
2022
Q1
Sell
-10,000
Closed -$81K 13682
2021
Q4
$81K Sell
10,000
-2,400
-19% -$23.6K ﹤0.01% 12928
2021
Q3
$156K Sell
12,400
-7,200
-37% -$99.7K ﹤0.01% 12330
2021
Q2
$303K Sell
19,600
-13,200
-40% -$222K ﹤0.01% 11240
2021
Q1
$663K Buy
+32,800
New +$811K ﹤0.01% 9064
2019
Q3
Sell
-10,100
Closed -$158K 9209
2019
Q2
$158K Buy
+10,100
New +$180K ﹤0.01% 8328
2018
Q3
Sell
-9,300
Closed -$263K 9245
2018
Q2
$263K Buy
+9,300
New +$277K ﹤0.01% 7431

Other funds holding CLLS

Citadel Advisors's CLLS Position: Q1 2026 in Review

Citadel Advisors reduced its Cellectis (CLLS) stake by 54% in Q1 2026, selling an estimated $196K and leaving 44,315 shares worth $140K. The position accounts for ﹤0.01% of the portfolio, ranked #11740.

Citadel Advisors first reported a position in CLLS in Q1 2015 and has held it in 40 quarters since. The position peaked at $8.53M in Q4 2019. 32 funds tracked by Wall St. Rank hold CLLS as of Q1 2026.

  • Citadel Advisors held 44,315 shares of Cellectis worth $140K as of Q1 2026.
  • Citadel Advisors sold 51,112 Cellectis shares in Q1 2026, an estimated $196K.
  • Cellectis made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11740 holding.
  • Citadel Advisors first reported a position in Cellectis in Q1 2015 and has held it in 40 quarters since.
  • Citadel Advisors's Cellectis position peaked at $8.53M in Q4 2019.
  • 32 funds tracked by Wall St. Rank held Cellectis as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.